Dogwood Therapeutics develops new medicines for pain and neuropathic disorders as a development-stage biopharmaceutical company listed on Nasdaq under DWTX. Company news centers on its pain and neuropathy pipeline, including Halneuron®, a non-opioid NaV 1.7 analgesic in development for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist program for chemotherapy-related pain and neuropathy.
Recurring updates also cover clinical and regulatory developments, FDA designations and investigational-drug activity, intellectual-property work tied to synthetic Halneuron®, financial results, financing activity, shareholder communications, and licensing arrangements involving anti-viral assets such as IMC-1 and IMC-2.
Dogwood Therapeutics (DWTX) entered into a securities subscription agreement for a $5 million investment from its largest shareholder, a CK Life Sciences subsidiary. Dogwood will issue 4,098,360 common shares at $1.22 per share, priced at-the-market under Nasdaq rules, with no warrants or other derivative securities. The private placement is expected to close on or prior to October 29, 2026.
Dogwood expects the proceeds to advance Halneuron Phase 3 preparatory activities and extend operational runway through March 2027, by which time it expects to finalize a pivotal Phase 3 program design. Its ongoing HAL-CINP Phase 2b trial evaluates Halneuron against placebo in 239 patients with chemotherapy-induced neuropathic pain, with topline data expected in November 2026. The primary endpoint measures the change in weekly average daily pain intensity from baseline to week four.
Dogwood Therapeutics (Nasdaq: DWTX) will participate in the 2026 Maxim Growth Summit in New York from October 12–14, 2026. CEO and Chairman Greg Duncan will meet institutional investors in one-on-one sessions and engage with senior Maxim research analysts.
Dogwood has completed enrollment in its Halneuron Phase 2b trial and anticipates topline results in November 2026. Portions of the summit will also be streamed online.
Dogwood Therapeutics (DWTX) has completed enrollment of 239 patients in its ongoing Phase 2b HAL-CINP trial of Halneuron® for chemotherapy induced neuropathic pain, reaching the upper end of its planned enrollment range, with topline data expected in November 2026.
The company states that positive results would be a major milestone for patients with CINP, which currently has no FDA-approved treatments. HAL-CINP (NCT06848348) is a randomized Phase 2b study at about 25 U.S. sites comparing Halneuron® with placebo in patients with moderate to severe neuropathic pain caused by prior platinum and/or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days and are followed for 28 days. The primary endpoint is change from baseline to week four in the weekly average of daily 24-hour recall pain intensity scores, with secondary measures assessing effects on sleep, fatigue, neuropathy symptoms and overall health.
Dogwood Therapeutics (Nasdaq: DWTX) will host a virtual key opinion leader event on September 1, 2026 at 10:00 AM ET to discuss Halneuron® for treating chemotherapy induced neuropathic pain (CINP). Expert speakers and management will cover the NaV 1.7 pain-signaling mechanism, Halneuron’s selective non-opioid profile, and prior pre-clinical and clinical data.
According to Dogwood Therapeutics, the event will also review positive interim results from the ongoing randomized Phase 2b CINP trial (HAL-CINP; NCT06848348), where 210–240 U.S. patients receive 8 subcutaneous doses over 14 days, and will discuss synthetic Tetrodotoxin manufacturing to support planned Phase 3 development.
Dogwood Therapeutics (Nasdaq: DWTX) reported second quarter 2026 results and clinical progress. The Phase 2b Halneuron® trial in chemotherapy‑induced neuropathic pain has enrolled 217 patients, with top‑line data expected in fall 2026, and a 12‑week open‑label extension study has begun. SP16 IV received FDA IND clearance, with a Phase 1b CIPPN trial to start in second‑half 2026, fully funded by the National Cancer Institute.
Dogwood reported Q2 2026 research and development expenses of $3.2 million and general and administrative expenses of $1.6 million. A non‑cash IPR&D impairment of $9.2 million, partly offset by a $2.5 million deferred tax benefit, led to a net loss of $11.5 million. Cash of $9.6 million is expected to fund operations through the Phase 2b readout in Q4 2026. The company also highlighted a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million and noted payments could benefit holders of its October 2024 CVRs.
Dogwood Therapeutics (Nasdaq: DWTX) reported enrollment of the first 200 patients in its ongoing HAL-CINP Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain. According to the company, the early termination rate among these patients is 4.5%, suggesting Halneuron and placebo have been well tolerated so far.
An independent statistical review committee previously examined unblinded data and concluded Halneuron-treated patients showed separation from placebo in pain improvement over four weeks. HAL-CINP is a randomized trial in approximately 210–240 patients at about 25 U.S. sites, using 8 subcutaneous doses over 14 days and 28 days of follow-up. The primary endpoint is change from baseline to week four in average daily 24-hour recall pain intensity scores, with top-line data expected in fall 2026.
Dogwood Therapeutics (Nasdaq:DWTX) appointed biopharma executive and OrbiMed venture partner Iain Dukes, Ph.D., as Chair of its newly formed Scientific Advisory Board. He will advise on Dogwood’s pipeline, including Halneuron in chemotherapy-induced neuropathic pain with Phase 2b data projected for fall 2026, and SP16, cleared by the FDA for Phase 1b in chemotherapy-induced peripheral neuropathy.
Dogwood Therapeutics (NASDAQ:DWTX) began a 12-week open-label Phase 2b extension study of Halneuron for chemotherapy induced neuropathic pain (CINP). The trial follows a positive interim assessment of a 4-week double-blind study and will collect additional safety and efficacy data.
Interim analysis based on 97 patients supported continuing the Phase 2b trial with a 210–240 patient sample to achieve 80% power. Top-line Phase 2b results are expected in fall 2026, with a Phase 3 program projected to start in the first half of 2027.
Dogwood Therapeutics (Nasdaq:DWTX) reported Q1 2026 results and pipeline progress. The Halneuron® Phase 2b CINP trial has enrolled 164 patients, with top-line data expected in fall 2026. SP16 received FDA IND clearance for a fully NCI-funded Phase 1b CIPPN trial.
The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100M. Q1 2026 R&D expenses were $2.7M and G&A $2.4M. Net loss was $5.0M ($0.15/share). Cash of $13.2M is expected to fund operations into Q4 2026.
Dogwood Therapeutics (Nasdaq: DWTX) will report its first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. Investors can expect a standard quarterly release and any accompanying investor materials or conference information to be shared around that time.